Schering AG, Germany, Announces European Approval for Radioimmunotherapy Product Zevalin

BERLIN, PRNewswire/ -- Zevalin(R) combines the targeting ability of an anti-CD20 monoclonal antibody with the cytotoxic power of beta radiation emitted by the Yttrium-90 isotope (Ytracis(R)) -- a pure beta emitter radiopharmaceutical -- to effectively destroy lymphoma cells. Radioimmunotherapy with Zevalin(R) has been shown to be effective in patients who were refractory to antibody treatment thus offering a new prospect for improving the quality of life for these patients.

What: Journalists are invited to access a live webcast to learn more about this novel treatment

When: Monday, January 26, 2003 (8:30 A.M. GMT / 9:30 A.M. CET)

PANELISTS: David Guy (Moderator) Vice President, Strategic Marketing & Business Development, Oncology Specialized Therapeutics, Schering AG Group Dr. Anton Hagenbeek
University Medical Center Utrecht (UMCU) (The Netherlands) Dr. Tim Illidge University of Southampton School of Medicine (United Kingdom) Dr. Joachim Kalmus Core Clinician, Clinical Development Oncology, Specialized Therapeutics Europe, Schering AG, Berlin

WHY: NHL is the fifth most common cancer in the world, after breast, prostrate, lung and colon cancer. An estimated
230,000 people are now living with this disease in the
European Union, with approximately 70,000 new cases diagnosed
each year. This incidence is currently increasing in Europe
by four percent per year.

Login information:
URL Address: www.schering.de
Instructions: Real Player or Windows Media Player software will be required for the webcast.
Help Line: +49-69-75-085-720

Additional information: Schering AG press release at www.Schering.de

Your contacts at Corporate Communication:
Pharma: Frank Richtersmeier, T: +49-30-468-176-61; frank.richtersmeier@schering.de
Media: Glenn Silver, T: +1-212-299-8975; glenn.silver@pr21.com
Vanessa Kelepecz, T: +1-212-299-3958; vanessa.kelepecz@pr21.com

This media alert has been published by Corporate Communication of Schering AG, Berlin, Germany.

Web site: http://www.Schering.de
per maggiori informazioni: Pharma: Frank Richtersmeier, T: +49-30-468-176-61; frank.richtersmeier@schering.de, Media: Glenn